Literature DB >> 14555548

The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis.

Shunji Tajima1, Katsuhisa Oshikawa, Shin-ichi Tominaga, Yukihiko Sugiyama.   

Abstract

BACKGROUND: The human ST2 gene can be specifically induced by growth stimulation in fibroblastic cells, and the soluble ST2 protein (ST2) is expressed preferentially in T-helper type 2 (Th2) cells. Furthermore, ST2 is induced by proinflammatory stimuli such as tumor necrosis factor-alpha and interleukin-1 beta. It has been reported that the inflammatory response in idiopathic pulmonary fibrosis (IPF) is thought to be associated with proinflammatory cytokines and Th2 immune response. STUDY
OBJECTIVE: The objective of this study was to evaluate the relevance of the serum ST2 levels in the pathogenesis of IPF.
DESIGN: Retrospective study.
SETTING: Inpatients in a college hospital. PARTICIPANTS: Forty-nine patients with IPF admitted to our hospital 64 times: 36 patients were admitted once, 11 patients were admitted twice, and 2 patients were admitted three times. The participants also included 200 healthy control volunteers. MEASUREMENTS AND
RESULTS: Among 64 events in 49 patients with IPF, 50 of the events occurred in a stable state, and 14 events occurred during acute exacerbation. An acute exacerbation of IPF was defined as an accelerated phase of IPF. The serum ST2 levels were measured by enzyme-linked immunosorbent assay. The serum levels of ST2 in the stable state group did not differ from those in the healthy control group, while the serum levels of ST2 in the acute exacerbation group were significantly higher than those in the stable state group or the healthy control group (p < 0.001, acute exacerbation group vs stable state group or healthy control group; acute exacerbation group, 2.76 +/- 0.56 ng/mL; stable state group, 0.44 +/- 0.07 ng/mL; healthy control group, 0.42 +/- 0.03 ng/mL). Furthermore, serum ST2 statistically correlated with lactate dehydrogenase (r = 0.344, p = 0.005) and C-reactive protein (r = 0.496, p < 0.001), and inversely correlated with PaO(2) (r = - 0.356, p = 0.018) and the percentage of predicted vital capacity (r = - 0.346, p = 0.026).
CONCLUSIONS: These results suggest that ST2 protein may increase in the serum, reflecting severity in the inflammatory process and Th2 immune response in the IPF lung.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555548     DOI: 10.1378/chest.124.4.1206

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  49 in total

Review 1.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

2.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Kazuhisa Konishi; Kevin F Gibson; Kathleen O Lindell; Thomas J Richards; Yingze Zhang; Rajiv Dhir; Michelle Bisceglia; Sebastien Gilbert; Samuel A Yousem; Jin Woo Song; Dong Soon Kim; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2009-04-10       Impact factor: 21.405

Review 3.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 4.  IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?

Authors:  Xuefeng Xu; Jinglan Zhang; Huaping Dai
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-04

Review 5.  IL-33/ST2 axis in inflammation and immunopathology.

Authors:  Marija Milovanovic; Vladislav Volarevic; Gordana Radosavljevic; Ivan Jovanovic; Nada Pejnovic; Nebojsa Arsenijevic; Miodrag L Lukic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

6.  Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome.

Authors:  Jehan W Alladina; Sean D Levy; Kathryn A Hibbert; James L Januzzi; R Scott Harris; Michael A Matthay; B Taylor Thompson; Ednan K Bajwa
Journal:  Crit Care Med       Date:  2016-09       Impact factor: 7.598

7.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.

Authors:  Erin E Coglianese; Martin G Larson; Ramachandran S Vasan; Jennifer E Ho; Anahita Ghorbani; Elizabeth L McCabe; Susan Cheng; Michael G Fradley; Dana Kretschman; Wei Gao; George O'Connor; Thomas J Wang; James L Januzzi
Journal:  Clin Chem       Date:  2012-10-11       Impact factor: 8.327

Review 8.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

9.  Soluble ST2 plasma concentrations predict mortality in severe sepsis.

Authors:  Jacobien J Hoogerwerf; Michael W T Tanck; Marieke A D van Zoelen; Xavier Wittebole; Pierre-François Laterre; Tom van der Poll
Journal:  Intensive Care Med       Date:  2010-02-12       Impact factor: 17.440

10.  Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD.

Authors:  Stefan Hacker; Christopher Lambers; Andreas Pollreisz; Konrad Hoetzenecker; Michael Lichtenauer; Andreas Mangold; Tina Niederpold; Andreas Hacker; György Lang; Martin Dworschak; Thomas Vukovich; Christopher Gerner; Walter Klepetko; Hendrik Jan Ankersmit
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.